InnoBioPharma has developed several novel drug candidates (two in pre-clinical trials) that are particularly effective against aggressive cancers that lack effective drug therapy. Cancers such as triple-negative breast cancer (TNBC), melanoma, and brain cancers are often resilient to many of the current treatments used to battle cancer. InnoBioPharma has solved this problem by observing naturally found anti-cancer compounds, synthesizing them or their structural analogs, and building a patent portfolio to pursue commercialization. These compounds will first be used to target triple-negative breast cancer.

Every year in the US alone there are 235,000 new cases of breast cancer, with about 40,000 cases diagnosed as drug resistant TNBC. InnoBioPharma will be able to fight cancers that have previously been impervious to medicine. As compared to existing drugs, these compounds are 10-100 times more effective against many drug-resistant cancers with little toxicity towards normal cells. Currently InnoBioPharma has moved two compounds from the discovery stage to preclinical trials, achieved with less than $2 million in non-dilutive funding, and acquired partners such as the NIH and MD Anderson Cancer Center. 

Venture Information
Stage: 
Pre-Clinical
Technology or Science Area: 
Oncology
Market: 
Drug Discovery and Development
Funding Round: 
Angel
Company Information
Founders: 
Zhendong Jin, PhD